Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3271625 | 1.00 | PDE4B (0.58) | PDE4BCTSKCTSLKMT2AL3MBTL1 | |
| SCHEMBL746618 | 1.00 | PDE4B (0.58) | PDE4BCTSKCTSLKMT2AL3MBTL1 | |
| SCHEMBL1359584 | 1.00 | PDE4B (0.58) | PDE4BCTSKCTSLKMT2AL3MBTL1 | |
| SCHEMBL12322673 | 1.00 | PDE4B (0.58) | PDE4BCTSKCTSLKMT2AL3MBTL1 | |
| SCHEMBL2517510 | 1.00 | PDE4B (0.58) | PDE4BCTSKCTSLKMT2AL3MBTL1 | |
| SCHEMBL23938305 | 1.00 | PDE4B (0.58) | PDE4BCTSKCTSLKMT2AL3MBTL1 | |
| SCHEMBL19064067 | 0.91 | CTSK (0.56) | PDE4BCTSKCTSLKMT2AL3MBTL1 | |
| SCHEMBL2537459 | 0.91 | CTSK (0.56) | PDE4BCTSKCTSLKMT2AL3MBTL1 | |
| SCHEMBL2534996 | 0.91 | CTSK (0.56) | PDE4BCTSKCTSLKMT2AL3MBTL1 | |
| SCHEMBL2992126 | 0.91 | CTSK (0.56) | PDE4BCTSKCTSLKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035154-A1 | Modulators of Cellular Adhesion | SARcode Bioscience, Inc. (US) | 2012-02-09 | — | — | US | disclosed |
| US-7989626-B2 | Modulators of cellular adhesion | SAR code Corporation (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110124625-A1 | Modulators of Cellular Adhesion | SARCODE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-7928122-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790743-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-7745460-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | PDE4B 2048/4885CTSK 4046/4885CTSL 1267/4885 |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | PDE4B 2029/4885CTSK 4034/4885CTSL 1246/4885 |
| US-20110124625-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | PDE4B 2048/4885CTSK 4046/4885CTSL 1267/4885 |
| US-20120035154-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | PDE4B 2048/4885CTSK 4046/4885CTSL 1267/4885 |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | PDE4B 2065/4885CTSK 4049/4885CTSL 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.